Active Ingredient History
Fondaparinux is a synthetic and specific inhibitor of activated Factor X (Xa). By selectively binding to antithrombin III (ATIII), fondaparinux sodium potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits thrombin formation and thrombus development. Fondaparinux is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): in patients undergoing hip fracture surgery, including extended prophylaxis; in patients undergoing hip replacement surgery; in patients undergoing knee replacement surgery; in patients undergoing abdominal surgery who are at risk for thromboembolic complications. The most serious adverse reactions reported with Fondaparinux are bleeding complications and thrombocytopenia. Agents that may enhance the risk of hemorrhage should be discontinued prior to initiation of therapy with Fondaparinux unless these agents are essential. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Venous Thrombosis (approved 2001)
Ablation Techniques (Phase 4)
Acute Coronary Syndrome (Phase 4)
Arthroplasty (Phase 4)
Arthroplasty, Replacement, Knee (Phase 4)
Atrial Fibrillation (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Coronary Artery Bypass (Phase 3)
Coronary Disease (Phase 2)
Coronavirus Infections (Phase 2)
COVID-19 (Phase 4)
Embolism (Phase 3)
Embolism and Thrombosis (Phase 2)
Endometrial Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
General Surgery (Phase 4)
Geriatrics (Phase 4)
Hip Injuries (Phase 3)
Knee Injuries (Phase 3)
Myocardial Infarction (Phase 2)
Neoplasms (Phase 3)
Obesity, Morbid (Phase 1)
Ovarian Neoplasms (Phase 2)
Pneumonia, Viral (Phase 2)
Pulmonary Embolism (Phase 4)
Renal Insufficiency (Phase 4)
Respiratory Insufficiency (Phase 2)
Sarcoma (Phase 2)
Thrombocytopenia (Phase 4)
Thromboembolism (Phase 4)
Thrombosis (Phase 4)
Uterine Cervical Neoplasms (Phase 2)
Vaginal Neoplasms (Phase 2)
Venous Thromboembolism (Phase 4)
Venous Thrombosis (Phase 3)
Vulvar Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue